Approval · Notice of Compliance 29403 · 2022
TEVA-PROPOFOL: Notice of Compliance 29403
Issued November 8, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29403
- Date
- November 8, 2022
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph and Package Insert
- Canadian reference product
- DIPRIVAN (Aspen Pharmacare Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-PROPOFOL | Not yet assigned | — |
Medicinal ingredients
- PROPOFOL 10 MG per ML